Almirall, Forest Get EU, FDA Nods For COPD Treatment

Law360, Washington (July 24, 2012, 7:30 PM EDT) -- Almirall SA and Forest Laboratories Inc.'s inhaled chronic obstructive pulmonary disease drug received U.S. Food and Drug Administration and European regulatory approval this week, the companies announced Tuesday.

The twice-daily inhaled dry powder, aclidinium bromide, helps treat bronchospasms, or the constricting of airways, that occur during COPD. The treatment will be sold under the name Tudorza Pressair in the U.S. and Eklira/Bretaris Genuair in the EU.

COPD, which includes chronic bronchitis and emphysema, is an inflammation of the airways that is often associated with smoking. The...
To view the full article, register now.